Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer.
Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0-4.9).
Takigawa
N
N
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan. ntakigaw@md.okayama-u.ac.jp
Kiura
K
K
Segawa
Y
Y
Watanabe
Y
Y
Kamei
H
H
Moritaka
T
T
Shibayama
T
T
Ueoka
H
H
Gemba
K
K
Yonei
T
T
Tabata
M
M
Shinkai
T
T
Hiraki
S
S
Takemoto
M
M
Kanazawa
S
S
Matsuo
K
K
Tanimoto
M
M
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000175:diagnosis*; D016019:Survival Analysis; D017741:Survivors; D043823:Taxoids / Q000008:administration & dosage; D013997:Time Factors
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil